Effectiveness of a Total Meal Replacement Program (OPTIFAST Program) on Weight Loss: Results from the OPTIWIN Study

Jamy D Ard, Kristina H Lewis, Amy Rothberg, Anthony Auriemma, Sally L Coburn, Sarah S Cohen, Judy Loper, Laura Matarese, Walter J Pories, Seletha Periman, Jamy D Ard, Kristina H Lewis, Amy Rothberg, Anthony Auriemma, Sally L Coburn, Sarah S Cohen, Judy Loper, Laura Matarese, Walter J Pories, Seletha Periman

Abstract

Objective: The aim of this study was to test the effectiveness of the OPTIFAST program (OP), a total meal replacement dietary intervention, compared with a food-based (FB) dietary plan for weight loss.

Methods: Participants with BMI 30 to 55 kg/m2 , age 18 to 70 years old, were randomized to OP or FB dietary and lifestyle interventions for 26 weeks, followed by a weight-maintenance phase. Outcomes were percent change in body weight (%WL) from baseline to weeks 26 and 52, associated changes in body composition (using dual energy x-ray absorptiometry), and adverse events. Primary analysis used repeated-measures multivariable linear mixed models to compare outcomes between groups in a modified intention-to-treat fashion (mITT).

Results: A total of 273 participants (83% of randomized; 135 OP, 138 FB) made up the mITT population. Mean age was 47.1 ± 11.2 years; 82% were female and 71% non-Hispanic white. Baseline BMI was 38.8 ± 5.9 kg/m2 . At 26 weeks, OP %WL was 12.4% ± 0.6% versus 6.0% ± 0.6% in FB (P < 0.001). At 52 weeks, OP %WL was 10.5% ± 0.6% versus 5.5% ± 0.6% in FB (P < 0.001). Fat mass loss was greater for OP; lean mass loss was proportional to total weight loss. There was no difference in serious adverse event rates between groups.

Conclusions: Compared with an FB approach, OP was more effective with greater sustained weight loss.

Trial registration: ClinicalTrials.gov NCT02635698.

© 2018 The Obesity Society.

Figures

Figure 1
Figure 1
CONSORT diagram.
Figure 2
Figure 2
Relative weight change by treatment group at 26 weeks and 52 weeks. Percent weight change values are calculated from a least square means from a linear mixed model. The linear mixed model contains a random intercept subject effect, fixed visit effect, fixed treatment effect, fixed baseline body weight effect, treatment‐by‐visit interaction term, and covariates including age, race, sex, site, and reported baseline diabetes status.
Figure 3
Figure 3
Proportion of participants who lost at least 5%, 10%, or 15% of initial body weight at weeks 26 and 52. *Significantly different from FB group at P < 0.001.

References

    1. Gardner CD, Trepanowski JF, Del Gobbo LC, et al. Effect of low‐fat vs low‐carbohydrate diet on 12‐month weight loss in overweight adults and the association with genotype pattern or insulin secretion: the DIETFITS randomized clinical trial. JAMA 2018;319:667‐679.
    1. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight‐loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859‐873.
    1. Jensen MD, Ryan DH, Donato KM, et al. Guidelines (2013) for managing overweight and obesity in adults. Obesity (Silver Spring) 2014;22(S2):S1‐S410.
    1. Heymsfield SB, van Mierlo CAJ, van der Knaap HCM, et al. Weight management using a meal replacement strategy: meta and pooling analysis from six studies. Int J Obes Relat Metab Disord 2003;27:537‐549.
    1. Keogh JB, Clifton PM. The role of meal replacements in obesity treatment. Obes Rev 2005;6:229‐234.
    1. Kahathuduwa CN, Davis T, O'Boyle M, et al. Effects of 3‐week total meal replacement vs. typical food‐based diet on human brain functional magnetic resonance imaging food‐cue reactivity and functional connectivity in people with obesity. Appetite 2018;120:431‐441.
    1. Heymsfield SB. Meal replacements and energy balance. Physiol Behav 2010;100:90‐94.
    1. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. Expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 1998;68:899‐917.
    1. Diabetes Prevention Program Research Group . The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care 2002;25:2165‐2171.
    1. Kramer MK, Kriska AM, Venditti EM, et al. Translating the Diabetes Prevention Program: a comprehensive model for prevention training and program delivery. Am J Prev Med 2009;37:505‐511.
    1. Knowler WC, Barrett‐Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393‐403.
    1. Tsai AG, Wadden TA. The evolution of very‐low‐calorie diets: an update and meta‐analysis. Obesity (Silver Spring) 2006;14:1283‐1293.
    1. Vazquez C, Montagna C, Alcaraz F, et al. Meal replacement with a low‐calorie diet formula in weight loss maintenance after weight loss induction with diet alone. Eur J Clin Nutr 2009;63:1226‐1232.
    1. Agras WS, Berkowitz RI, Arnow BA, et al. Maintenance following a very‐low‐calorie diet. J Consult Clin Psychol 1996;64:610‐613.
    1. Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr 2015;101:1320S‐1329S.
    1. Lean ME, Leslie WS, Barnes AC, et al. Primary care‐led weight management for remission of type 2 diabetes (DiRECT): an open‐label, cluster‐randomised trial. Lancet 2017;391:541‐551.
    1. Herman WH, Brandle M, Zhang P, et al. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care 2003;26:36‐47.
    1. Diabetes Prevention Program Research Group . The 10‐year cost‐effectiveness of lifestyle intervention or metformin for diabetes prevention: an intent‐to‐treat analysis of the DPP/DPPOS. Diabetes Care 2012;35:723‐730.
    1. Rothberg AE, McEwen LN, Fraser T, et al. The impact of a managed care obesity intervention on clinical outcomes and costs: a prospective observational study. Obesity (Silver Spring) 2013;21:2157‐2162.
    1. Nuijten M, Marczewska A, Araujo Torres K, Rasouli B, Perugini M. A health economic model to assess the cost‐effectiveness of OPTIFAST for the treatment of obesity in the United States. J Med Econ 2018;21:835‐844.

Source: PubMed

3
Abonnieren